JP2015516806A5 - - Google Patents

Download PDF

Info

Publication number
JP2015516806A5
JP2015516806A5 JP2015503315A JP2015503315A JP2015516806A5 JP 2015516806 A5 JP2015516806 A5 JP 2015516806A5 JP 2015503315 A JP2015503315 A JP 2015503315A JP 2015503315 A JP2015503315 A JP 2015503315A JP 2015516806 A5 JP2015516806 A5 JP 2015516806A5
Authority
JP
Japan
Prior art keywords
patient
expression
vegf antagonist
gene
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015503315A
Other languages
English (en)
Japanese (ja)
Other versions
JP6335875B2 (ja
JP2015516806A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/031760 external-priority patent/WO2013148288A1/en
Publication of JP2015516806A publication Critical patent/JP2015516806A/ja
Publication of JP2015516806A5 publication Critical patent/JP2015516806A5/ja
Application granted granted Critical
Publication of JP6335875B2 publication Critical patent/JP6335875B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015503315A 2012-03-30 2013-03-14 癌の治療のための診断法及び組成物 Expired - Fee Related JP6335875B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261618199P 2012-03-30 2012-03-30
US61/618,199 2012-03-30
PCT/US2013/031760 WO2013148288A1 (en) 2012-03-30 2013-03-14 Diagnostic methods and compositions for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017229130A Division JP2018075015A (ja) 2012-03-30 2017-11-29 癌の治療のための診断法及び組成物

Publications (3)

Publication Number Publication Date
JP2015516806A JP2015516806A (ja) 2015-06-18
JP2015516806A5 true JP2015516806A5 (https=) 2016-05-12
JP6335875B2 JP6335875B2 (ja) 2018-05-30

Family

ID=49261061

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015503315A Expired - Fee Related JP6335875B2 (ja) 2012-03-30 2013-03-14 癌の治療のための診断法及び組成物
JP2017229130A Pending JP2018075015A (ja) 2012-03-30 2017-11-29 癌の治療のための診断法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017229130A Pending JP2018075015A (ja) 2012-03-30 2017-11-29 癌の治療のための診断法及び組成物

Country Status (14)

Country Link
US (1) US20150056190A1 (https=)
EP (1) EP2830661A4 (https=)
JP (2) JP6335875B2 (https=)
KR (1) KR20140142719A (https=)
CN (1) CN104271157A (https=)
AU (2) AU2013240234B2 (https=)
BR (1) BR112014024219A8 (https=)
CA (1) CA2867588A1 (https=)
HK (1) HK1200739A1 (https=)
IL (1) IL234678A0 (https=)
MX (1) MX2014011582A (https=)
RU (1) RU2666627C2 (https=)
SG (2) SG10201509939PA (https=)
WO (1) WO2013148288A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
JP2015096049A (ja) * 2013-11-15 2015-05-21 凸版印刷株式会社 Ｖｅｇｆ阻害剤長期奏功性予測方法
WO2015082880A1 (en) * 2013-12-02 2015-06-11 Astrazeneca Ab Methods of selecting treatment regimens
WO2016011052A1 (en) * 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
EP3194972B1 (en) * 2014-09-17 2021-04-14 Merck Patent GmbH A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
WO2016041614A1 (en) 2014-09-17 2016-03-24 Merck Patent Gmbh A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof
CA2963091A1 (en) * 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
KR20170094165A (ko) * 2014-12-23 2017-08-17 제넨테크, 인크. 화학요법-내성 암을 치료 및 진단하는 조성물 및 방법
EP3550305A4 (en) * 2016-12-01 2020-11-11 Santen Pharmaceutical Co., Ltd. METHOD OF PREDICTING THE EFFECTIVENESS OF AN ANTI-VEGF ACTIVE INGREDIENT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
KR20200005540A (ko) * 2017-04-14 2020-01-15 제넨테크, 인크. 암의 진단 및 치료 방법
US12016900B2 (en) 2017-06-04 2024-06-25 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
US12070489B2 (en) 2018-12-12 2024-08-27 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with a cancer therapy in combination with another therapeutic agent
WO2018225063A1 (en) * 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor
RU2701356C1 (ru) * 2018-09-18 2019-09-25 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) Способ диагностики рака молочной железы с экспрессией рецептора Her2/neu на мембране опухолевых клеток
US11793889B2 (en) * 2018-09-24 2023-10-24 Kinase Pharma Inc. Methods for selective kinase inhibition by endogenously produced antagonists of one or more kinases
CN110714078B (zh) * 2019-09-29 2021-11-30 浙江大学 一种用于ii期结直肠癌复发预测的标记基因及应用
GB202007099D0 (en) * 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
EP4099219A1 (en) * 2021-06-02 2022-12-07 Siemens Healthcare GmbH Method and device for determining presence of tumor
WO2023017525A1 (en) 2021-08-11 2023-02-16 OncoHost Ltd. Predicting patient response
CN115840046A (zh) * 2022-08-17 2023-03-24 中国药科大学 一种鉴别anti-VEGF抗体获得性耐药的蛋白聚糖ESM1生物学标记物及其应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP1140137A2 (en) * 1998-12-18 2001-10-10 Scios Inc. Method for detection and use of differentially expressed genes in disease states
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
WO2001075166A2 (en) 2000-03-31 2001-10-11 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
KR20030074693A (ko) 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20060084064A1 (en) * 2003-01-22 2006-04-20 Aird William C Endocan compositions and methods for the treatment of neoplasms
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20060008823A1 (en) 2004-05-12 2006-01-12 Kemp Jennifer T DNA profiling and SNP detection utilizing microarrays
WO2007047955A2 (en) * 2005-10-21 2007-04-26 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
RU2415869C2 (ru) * 2006-06-06 2011-04-10 Дженентек, Инк. Антитела против dll4 и способы их применения
AU2008205543A1 (en) * 2007-01-18 2008-07-24 University Of Southern California Genetic markers for predicting responsiveness to combination therapy
CA2705152C (en) * 2007-11-09 2016-10-11 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
AU2010273585B2 (en) * 2009-07-13 2015-04-23 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
EP2464744A1 (en) * 2009-08-14 2012-06-20 F. Hoffmann-La Roche AG Biological markers for monitoring patient response to vegf antagonists

Similar Documents

Publication Publication Date Title
JP2015516806A5 (https=)
RU2014143805A (ru) Способы диагностики и композиции для лечения рака
Uribesalgo et al. Apelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy
Keskin et al. Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2
JP2015512612A5 (https=)
Lu et al. lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling
McClellan et al. Linking tumor-associated macrophages, inflammation, and intestinal tumorigenesis: role of MCP-1
Leto et al. Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
Pathak et al. Role of angiogenesis and its biomarkers in development of targeted tumor therapies
Shen et al. Tumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin
Zhang et al. Apelin as a marker for monitoring the tumor vessel normalization window during antiangiogenic therapy
Kim et al. S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy
RU2016111161A (ru) Диагностические способы и композиции для лечения глиобластомы
RU2014133164A (ru) Биологические маркеры для идентификации пациентов для лечения антагонистами vegf
Brunckhorst et al. Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis
JP2017523776A5 (https=)
Chi et al. Inhibition of angiogenesis and invasion in malignant gliomas
Han et al. CXCR1 knockdown improves the sensitivity of osteosarcoma to cisplatin
Li et al. Effects of recombinant human endostatin and its synergy with cisplatin on circulating endothelial cells and tumor vascular normalization in A549 xenograft murine model
Robles Irizarry et al. Therapeutic targeting of VEGF in the treatment of glioblastoma
JP2017527533A5 (https=)
Feng et al. Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer
Meynard et al. Inflammation regulates TMPRSS6 expression via STAT5
Singh et al. Idiopathic pulmonary fibrosis: where do we stand and how far to go
Jing et al. Down-expression of miR-373 predicts poor prognosis of glioma and could be a potential therapeutic target